Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-26T06:29:08.443Z Has data issue: false hasContentIssue false
  • English
  • Français

Relationship between circadian rhythm and Malondialdehyde serum levels in acute and stabilized schizophrenic patients

Published online by Cambridge University Press:  27 August 2024

E. Díaz-Mesa ,
C. Cárdenes Moreno ,
A. Morera-Fumero ,
I. Perez-Sagaseta De Ilurdoz ,
P. Abreu-González ,
M. R. Cejas-Méndez ,
M. L. Fernández-López  and
M. S. Henry-Benítez
E. Díaz-Mesa
Affiliation:
1PSIQUIATRÍA, HOSPITAL UNIVERSITARIO DE CANARIAS 2MEDICINA INTERNA, PSIQUIATRÍA Y DERMATOLOGÍA
C. Cárdenes Moreno
Affiliation:
1PSIQUIATRÍA, HOSPITAL UNIVERSITARIO DE CANARIAS
A. Morera-Fumero
Affiliation:
2MEDICINA INTERNA, PSIQUIATRÍA Y DERMATOLOGÍA
I. Perez-Sagaseta De Ilurdoz*
Affiliation:
1PSIQUIATRÍA, HOSPITAL UNIVERSITARIO DE CANARIAS
P. Abreu-González
Affiliation:
3FISIOLOGÍA, UNIVERSIDAD DE LA LAGUNA, SAN CRISTOBAL DE LA LAGUNA, Spain
M. R. Cejas-Méndez
Affiliation:
1PSIQUIATRÍA, HOSPITAL UNIVERSITARIO DE CANARIAS 2MEDICINA INTERNA, PSIQUIATRÍA Y DERMATOLOGÍA
M. L. Fernández-López
Affiliation:
2MEDICINA INTERNA, PSIQUIATRÍA Y DERMATOLOGÍA
M. S. Henry-Benítez
Affiliation:
2MEDICINA INTERNA, PSIQUIATRÍA Y DERMATOLOGÍA
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Malondialdehyde (MDA) is a product of polyunsaturated fatty acid peroxidation (Del Rio D, et al. A review of recent studies on MDA as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis. 2005;15:316-28). It is a biomarker of oxidative stress and is involved in the pathophysiology of schizophrenia (Goh et al. Asian J Psychiatr. 2022;67:102932). Schizofrenia is linked to disrupted oxidative balance and inflammation (Więdłocha et al. Brain Sci. 2023;13:490). Prior research has shown connections between biomarkers and circadian rhythms in schizophrenia (Morera & Abreu. Acta Physiol Scand. 2007;43:313-14) and diabetes type 2 (Kanabrocki EL, et al. Circadian variation in oxidative stress biomarkers in healthy and type II diabetic men. Chronobiol Int. 2002;19:423-39). To determinate if MDA levels have a role in schizophrenia and follow a circadian rhythm may be useful.

Objectives

The aim of our study is to compare diurnal and nocturnal MDA serum levels in patients in acute and stabilized phases of schizophrenia according to CIE-10 to find out if there are variations related with circadian rhythms

Methods

47 patients were included in our study in two clinical phases: acute episode and stabilization. Blood samples were collected at 12:00h and at 00:00h. MDA serum levels were measured twice: when patients were decompensated (admission) and at clinical stabilization (discharge). The relationship between quantitative variables at both times was analysed by T-Student test

Results

There is no significative difference between night and day MDA levels in the acute phase of the schizophrenia (2.22±1.352 vs. 1.93±1.530, p<0.09). There is statistical significance between 12:00 and 00:00 (1.90±1.136 vs. 1.34±0.868, p<0.001) at discharge: it was observed that levels decreased. This result can be interpreted as there is circadian rhythm in stabilized phases.

Conclusions

MDA levels in patients with schizophrenia do not follow a circadian rhythm in the acute episode. When they are clinically stabilized present a circadian change. These patients lose the circadian rhythm in acute episodes. MDA circadian rhythm may help diagnose the clinical phase and its severity. It is necessary to perform more studies to know its utility as an oxidative biomarker

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 67 , Special Issue S1: Abstracts of the 32nd European Congress of Psychiatry , April 2024 , pp. S759
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.